Troy Noordenbos

Employment

• Leiden University Medical Center Postdoc
  2023 - 2026

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (20)

• Anatomical Origin Defines Tumor–Immune Archetypes in Diffuse Large B-Cell Lymphoma
  2026 DOI: 10.2139/ssrn.7279068
  +Save
• Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone (CHEPA) in newly diagnosed CD30-positive peripheral T-cell lymphomas with integrated ctDNA analysis: Results of the phase 2 CHEPA trial.
  2026 DOI: 10.1200/JCO.2026.44.16_suppl.7081
  +Save
• A unified spatial & molecular atlas of anatomically restricted large B-cell lymphomas defines stereotyped cell ecosytems
  2025 DOI: 10.1182/blood-2025-3555
  +Save
• Distinct morphological features of malignant cells in large B-cell lymphoma identified by soft-segmentation in imaging-based spatial proteomics
  2025 DOI: 10.1182/blood-2025-4342
  +Save
• Multimodal discovery of distinct tumor ecosystems for classic Hodgkin lymphoma
  2025 DOI: 10.1182/blood-2025-1783
  +Save
• CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias.
  Research square 2025 DOI: 10.21203/rs.3.rs-7746241/v1
  +Save
• Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma.
  Nature communications 2025 DOI: 10.1038/s41467-025-63339-9
  +Save
• Superior survival in diffuse large B cell lymphoma of the bone with immune rich tumor microenvironment.
  Blood cancer journal 2025 DOI: 10.1038/s41408-025-01291-z
  +Save
• Immunosuppressed Tumor Microenvironment in MYC-Rearranged High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas, Not Otherwise Specified
  2024 DOI: 10.1182/blood-2024-205968
  +Save
• Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy.
  The New England journal of medicine 2024 DOI: 10.1056/NEJMoa2401361
  +Save